BCL11A and sickle cell disease: An erythroid-specific enhancer of BCL11A located in an intron of the BCL11A gene is currently the target of multiple gene therapy trials aimed at restoring high levels of fetal hemoglobin to ameliorate disease in beta-hemoglobinopathies (see ‘fetal hemoglobin’ and ‘sickle cell disease’).